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1. Introduction 
1.1 Skin  
The evolution of life in the terrestrial environment required the development of a 
waterproof integument: the skin (Loden and Maibach, 2006). Skin is an extensive organ 
covering the entire exterior of the body (Stevens and Lowe, 2005). It provides the primary 
barrier against chemical and biological external agents and water loss (Hadgraft, 2001). The 
skin also plays an important role in thermoregulation, sensory perception and vitamin D 
metabolism (McKay and Leigh, 1995).  
The skin is composed of three main layers: the epidermis, the dermis and the hypodermis. 
The epidermis is the protective skin layer in contact with the external environment (Stevens 
and Lowe, 2005). This skin layer consists mainly of a stratified squamous keratinized 
epithelium (Junqueira and Carneiro, 2005). The epidermis cells, the keratinocytes, divide in 
the basal layer and differentiate throughout their migration to the surface. The epidermis is 
divided in 5 different layers (stratum basale, stratum spinosum, stratum granulosum, 
stratum lucidum and stratum corneum). The dermis is the feeder layer of the epidermis and 
provides most of the skin's mechanical resistance and elasticity. It is mainly composed of 
fibroblasts, epidermal appendages, blood vessels, nerves and nerve endings (Stevens and 
Lowe, 2005). Finally, the hypodermis is the deepest layer of the skin. It varies in size and 
content, but is usually composed of adipocytes which form the adipose tissue (Stevens and 
Lowe, 2005). Many severe skin diseases can be observed in human beings such as psoriasis. 
 
1.2 Psoriasis 
Epidemiology 
Psoriasis is an ancient chronic skin disease (Nickoloff and Nestle, 2004). Uncommon under 
the age of 10 years, it appears between the ages of 15 and 30 years affecting men and women 
(Fitzpatrick and Wolff, 2008). Psoriasis is universal in occurrence, but its prevalence in 
different populations varies from 0.1% to 11.8% (Raychaudhuri and Farber, 2001). In fact, 
this pathology shows a significant geographical variability with the lowest incidence seen at 
the equator and increasing frequency towards the poles (Kormeili et al., 2004). Psoriasis 
affects about 25 million people in North America and Europe (Lowes et al., 2007). 
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Characteristics 
Psoriasis is characterized by red and scaly plaques on the skin with a predilection for certain 
areas (elbows, knees and scalp) (Chapman et al., 1990; Lowes, et al., 2007). There are five 
clinical variants of psoriasis: guttate, erythrodermic, pustular, inverse and psoriasis vulgaris, 
the last of wich is the most common type seen in approximately 90% of patients (Fitzpatrick 
and Wolff, 2008). The severity can be divided into benign, moderate and severe psoriasis. 
Histological appearance of lesions shows elongation of the rete ridges, disappearance of the 
granular layer and persistence of the keratinocytes nuclei in the stratum corneum of the 
epidermis (Danilenko, 2008). In psoriasis, epidermal hyperproliferation, abnormal keratinocyte 
differentiation, angiogenesis with blood vessel dilatation and excess Th-1 and Th-17 
inflammation can be observed (Azfar and Gelfand, 2008). However, although genetic, 
immunological and environmental factors seem implied, the exact cause is not yet known and 
even today, psoriasis is not well understood (Bowcock, 2005).  
Treatments 
A broad spectrum of anti-psoriatic treatments, both topical and systemic, is available for the 
management of psoriasis (Fitzpatrick and Wolff, 2008). However, it is often resistant to 
treatment or, else, frequently relapses upon cessation of medication after partial or 
acceptable clearance is obtained (Kormeili, et al., 2004). The severity of the disease usually 
determines the therapeutic approach. Among the treatments, there are topical, 
phototherapy, biologic and systemic treatments (Table 1). Approximately, 70 to 80% of all 
patients with psoriasis can be treated adequately with topical therapy (Schon and Boehncke, 
2005). For others, phototherapy and systemic treatments are effective; however, the duration 
of a treatment is restricted because of the cumulative toxicity potential of an individual 
therapy (Kormeili, et al., 2004). For example, some treatments may increase the risk of 
cancer (phototherapy) while others can induce disorders in the liver (methotrexate) 
(Dubertret, 2004).  Sometimes, treatment efficacy may diminish with time and it must be 
replaced by another therapy (Fitzpatrick and Wolff, 2008). At the present time, there is still 
no curative treatment for psoriasis. 
 
Topical Phototherapy Biologic Systemic 
Corticosteroids Narrowband UVB Alefacept Cyclosporine A 
Vitamin D analogues Broadband UVB Efalizumab Methotrexate 
Tazarotene Psoralen-UVA Etanercept Acitretin 
Calcineurin inhibitors Excimer laser Infliximab Fumaric acid esters 
  Adalimumab Sulfasalazine 
   Mycophenolate mofetil 
   6-Thioguanine 
   Hydroxyurea 
Table 1. Anti-psoriatic treatments 
 
2. Tissue engineering  
Although conventional approaches for organ replacement, such as transplantation, 
autografts and implantation of engineered prostheses, are extensively used, the process by 
which a patient can regenerate a lost organ is more attractive (Yannas, 2004). Recent 
biotechnological progress in the tissue engineering field allows us to conceive, develop and 
produce biomaterials which can replace tissues or organs (Bernard et al., 2007). It has been 
demonstrated that tissue reconstruction can be applied to several different tissues such as 
skin, blood vessels, cartilage, bones and corneas (Arosarena, 2005). Tissue engineering can 
be used in experimental and clinical applications (Auger et al., 2004). 
 
3. In vivo and in vitro models versus pharmaceutical researches 
3.1 Development of drugs 
The development of a new drug takes approximately 20 years. During this period of time, 
pharmaceutical industries spend millions of dollars on the research for new, more effective 
drugs. The cost of bringing new drugs to the market has recently increased and today, it 
costs approximately 1 billion US dollars to bring a new medicine to the market. A large 
amount of research is devoted every year to the discovery of new pharmacologically 
effective substances and many molecules reach the level of pre-clinical and clinical phase 
trials. However, attrition rates in clinical development are still very high and up to 90 % of 
new compounds fail in clinical phases I-III (Zollner et al., 2004). Late-stage clinical failure 
can be, to a great extent, attributed to a lack of clinical efficacy, indicating a strong need for 
highly predictive in vivo and in vitro models. Consequently, the pharmaceutical industry 
stays alert for the development of more relevant pathological in vivo and in vitro models to 
improve the success rate of new drugs (Zollner, et al., 2004). Highly predictive models can 
easily translate into significant savings of time and money for the pharmacological industry. 
 
3.2 Experiments on psoriatic models  
Some models have already been used to evaluate the effect of various molecules on 
psoriasis. For example, a team tested an antibody directed against interleukin 15 that was 
known to inhibit the production of T lymphocytes as well as the liberation of TNF-α in vitro 
(Krueger and Bowcock, 2005). Application of this antibody on severe combined 
immunodeficient mice (SCID) led to the disappearance of psoriatic characteristics. This 
suggested that the molecule could be targeted for future studies to develop a new anti-
psoriatic treatment. 
 
4. In vivo models 
Animal models are very popular for the study of psoriasis. Many approaches are currently 
followed in order to obtain a representative animal model of the disease with all the 
characteristics of the human pathology. Many immunological and genetic models have been 
developed to date. However none of these models show all the characteristics of psoriasis. 
Researchers look for a perfect animal model which would have many genetic, histological 
and morphological similitudes with human beings and react to treatments in a similar way 
(Zollner, et al., 2004). Furthermore, the models must be easily reproducible, inexpensive and 
ethical.  
 
4.1 Spontaneous mutations  
Over the years, many mutations were described as being responsible for abnormal changes 
in the skin or hair of mice (Sundberg et al., 1990). Among these mutations, some were 
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studied for their psoriasis-like characteristics such as thickening of the skin and the 
formation of scales (Mizutani et al., 2003). However, the resulting mutants do not closely 
mimic the disease enough to be considered as good models of psoriasis. They must rather be 
used to compare local pathogenic events such hyperkeratosis, regulation of neutrophil 
infiltration and microabscess formation or dermal angiogenesis (Schon, 2008). Nearly a 
hundred mouse mutations that lead to psoriasiform phenotypes have been documented 
(Sundberg, et al., 1990).   
Homozygous asebia (Scd1ab/Scd1ab) 
The asebia mouse mutation was one of the first in vivo models used to study therapies 
directed at hyperkeratotic disorders (Schon, 2008). These homozygous asebia mutant mice 
are characterized by a hypoplasia of the sebaceous glands resulting from a defect in the 
stearoyl coenzyme A desaturase-1 (Scd1) gene (Zheng et al., 1999). This model exhibits 
moderate epidermal acanthosis, increased dermal vascularization, a dermal infiltrate 
composed of macrophages and mast cells, but neither T cells nor neutrophils (Schon, 2008). 
This lack of T cells and neutrophils do not mirror psoriatic lesions. Moreover, alterations of 
the cutaneous lipid metabolism seem different from psoriasis.  
Flaky skin mice (Ttcfsn/Ttcfsn) 
The spontaneous chronic proliferative dermatitis mutation (Sharpincpdm/Sharpincpdm) 
(HogenEsch et al., 1993) and the flaky skin (Sundberg, et al., 1990) mice show a more 
interesting psoriatic phenotype than homozygous asebia mice. The flaky skin mice are 
probably the best spontaneous model of psoriasis described (Danilenko, 2008). Its 
spontaneous mutation induces proliferation and hyperkeratosis of stratified squamous 
epithelia including the nonglandular forestomach (Stratis et al., 2006). Previous studies have 
shown a positive Koebner reaction after tape-stripping, which resolves after 6 weeks of 
treatment with oral, but not topical, cyclosporine A, topical EGF, or UVB exposure 
(Sundberg et al., 1994). The flaky skin phenotype is very complex and comprises aspects not 
present in psoriasis. To verify if plaques had an inflammatory origin, the mice were treated 
with cyclosporine. The results showed that immunosuppressive treatment had no effect on 
the psoriatic lesions of those mice. This observation demonstrated that such models are not 
complete because they lack the immunological side of the pathology (Schon, 1999).   
Spontaneous chronic proliferative dermatitis mutation 
The spontaneous chronic proliferative dermatitis mutation shows various characteristics 
found in psoriasis such as hyperproliferative skin, infiltration of inflammatory cells in the 
skin and dilation of blood vessels in the dermis (Schon, 1999). However, as with the flaky 
skin mice, the value of the spontaneous chronic proliferative dermatitis mutation for 
psoriasis research is limited by the lack of a T cell based immunopathogenesis. Moreover, as 
immunosuppressive therapeutic regimens used to treat psoriasis fail to improve skin lesions 
with these mutations, it appears uncertain whether they can be used to test potential 
therapeutic compounds (Schon, 1999).  
 
4.2 Genetically engineered models  
Genetically engineered mice represent the largest category of psoriasis models. These 
include the transgenic and knockout models. In this section, some of these models will be 
discussed. The complete list of in vivo psoriatic skin models can be seen in table 2. 
 
 
HLA-B27 rat 
The human leukocyte antigen B27 (HLA-B27) transgenic rats are normal at birth but develop 
chronic inflammation of multiple organ systems as they age (Keith et al., 2005). In this 
model, the human HLA-B27 and β2-microglobulin proteins are overexpressed and an 
epidermal acanthosis with epidermal infiltration of both CD4+ and CD8+ T cells, as well as 
immune-mediated arthritis and inflammatory bowel disease, which seem similar to the 
spondyloarthropathies in humans that have been associated with the HLA-B27 and β2-
microglobulin genes, such as acanthosis can be observed (Breban et al., 1996; Keith, et al., 
2005; Taurog et al., 1993; Yanagisawa et al., 1995). The HLA-B27 transgenic rat model has 
been used for several years to evaluate the activity and mechanisms of action of anti-
inflammatory molecules (Chadwick et al., 2005; Harnish et al., 2004; Peterson et al., 2002). 
Results show that broad-spectrum antibiotic therapy can produce significant remissions of 
inflammatory lesions, but relapse occurs when antibiotic therapy stops (Keith, et al., 2005). 
In this model, the occurrence of psoriatic skin lesions is less consistent than is the occurrence 
of the other immune-mediated disorders and there are no published reports of therapeutic 
efficacy testing for the psoriatic lesions (Danilenko, 2008; Taurog, et al., 1993; Yanagisawa, et 
al., 1995).  
CD18 hypomorphic 
The CD18 hypomorphic mice model targets leukocytes (Bullard et al., 1996). This model 
shows a decreased expression of the common β2 chain of the leukointegrin adhesion 
molecule complex (Danilenko, 2008). Beta2 integrins are leukocyte adhesion molecules 
exclusively expressed on hematopoietic cells  and are responsible for cell-cell contacts in a 
variety of inflammatory interactions (Kess et al., 2003). When the CD18 mutation was 
crossed onto the PL/J strain of mice, it developed a psoriasiform inflammatory skin 
condition with a predominantly lymphocyte infiltration (Bullard, et al., 1996). However, 
these mice exhibit nonpsoriasiform characteristics such as the absence of hyperproliferation 
markers.  
K14/VEGF and Tie2 
Mice overexpressing VEGF in epidermis via a keratin 14 promoter develop a phenotype 
very similar to psoriasis with an epidermal acanthosis, abnormal differentiation, 
inflammatory infiltrate and inflamed dermal blood vessels (Kunstfeld et al., 2004; Xia et al., 
2003). Even if this model has many immunological, vascular and epidermal resemblances 
with psoriasis, the lesions appear to be vascular-based and there is the presence of a major 
dermal infiltration of mast cells (Danilenko, 2008). Similar elements were observed in the 
Tie2 transgenic mice. With the activation of the transgene, the mice develop erythema with 
silver-white scaling, acanthosis, elongation of the rete ridges, hyperkeratosis, parakeratosis, 
increase in blood capillaries, infiltration of inflammatory cells and neutrophilic microabscess 
(Gudjonsson et al., 2007; Voskas et al., 2005). This model also reacts to cyclosporine A when 
used as a psoriatic therapy. 
K14/TGF-α, K5/TGF-β1, K14/KGF and K14/IL-20 
Many transgenic mice models were produced to target, via the keratin 5 or keratin 14 
promoter, the expression of epithelial growth factors such as TGF-α (Vassar and Fuchs, 
1991), TGF-β1 (Li et al., 2004) and KGF (Guo et al., 1993) into the basal layer. In each model, 
psoriasiform phenotype can be observed such as acanthosis, but no cutaneous inflammation 
is displayed into any of them. In the K14/IL-20 model, the expression of IL-20 was targeted 
to the basal layer under the control of a keratin 14 promoter (Blumberg et al., 2001). In this 
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model, some psoriatic characteristics can be observed such as abnormal keratinocyte 
differentiation and an expression of the keratin 6, a hyperproliferation marker (Blumberg, et 
al., 2001). However, the lack of inflammatory components is a severe drawback of this 
model, as it is for K14/TGF-α, K5/TGF-β1, K14/KGF models.  
IKK2 and JunB/c-Jun 
The immunological theory of psoriasis was challenged by more recent studies using animal 
models, including the IKK2 (Pasparakis et al., 2002) and JunB/c-Jun transgenic mice (Zenz 
et al., 2005). Results obtained with these two models have suggested revisiting the primary 
pathogenic role for epidermal keratinocytes. In the IKK2 knockout mice model, the deletion 
of the IKK2 catalytic subunit of the IκB kinase complex caused mice to develop a 
psoriasiform cutaneous inflammation (Pasparakis, et al., 2002). This model displays many 
features of psoriasis, including dependence on the dermal expression of TNF-α, acanthosis 
and abnormal differentiation. However, some characteristics of this model, such as T-cell-
independent inflammation, keratinocyte apoptosis and early death are not found in 
psoriasis (Pasparakis, et al., 2002; Stratis, et al., 2006). In the JunB/c-Jun mice model, JunB 
and c-Jun are knocked out in the epidermis of postnatal mice with Junbtm3Wag or Juntm4Wag, or 
both (Zenz, et al., 2005). In this model, affected skin areas showed infiltration of neutrophils 
and lymphocytes with upregulation of several cytokines and chemokines typical of 
psoriasis. However, other factors such as INF-γ were only slightly upregulated while IL-12 
or IL-18 were absent (Gudjonsson, et al., 2007). In this model, cutanous inflammation is not 
dependant on T cells nor is it independent of TNF signalling (Zenz, et al., 2005).     
K5.Stat3C 
The K5.Stat3C mice model is characterized by the activation of the signal transducer and 
activator of transcription 3 (Stat3) in basal keratinocytes under the control of the keratin 5 
promoter (Sano et al., 2005). Stat3 plays an important role in various biological activities 
including cell proliferation, survival and migration (Hirano et al., 2000). These mice 
developed psoriatic-like skin lesions characterized by a keratinocyte hyperplasia, a loss of 
the granular layer and parakeratosis. The presence of many dilated blood vessels and a 
leukocytic infiltration of lymphocytes and neutrophils were observed (Sano, et al., 2005). To 
generate a psoriatic phenotype in transplanted SCID mice, the injection of activated 
lymphocytes and the Stat3 transgenic skin are necessary. These results allow to establish a 
link between keratinocytes and CD4+ T lymphocytes in psoriasis (Danilenko, 2008). 
K14/IL-6 and K14/IL-1α 
A human keratin 14 promoter was used to express IL-6 in the basal cells of epidermal mice 
(Turksen et al., 1992). IL-6 expression did not lead to enhanced epidermal proliferation, but 
it did result in a thicker stratum corneum with an otherwise seemingly normal 
differentiation program. However, IL-6 expression did not lead to leukocytic infiltration 
(Turksen, et al., 1992). In 1995, Groves et al., observed characteristics of psoriasis in a 
transgenic mouse model that expresses high levels of interleukin 1α in basal epidermis. This 
model displayed many characteristics of psoriasis. Uninvolved skin of these animals was 
characterized by hyperkeratosis and dermal mononuclear cell infiltrate of  
macrophage/monocyte lineage (Groves et al., 1995). Inflammatory lesions were marked by 
a mixed cellular infiltrate, acanthosis and parakeratosis in some cases. These results strongly 
indicate that IL-1 is a cytokine which plays an important role in psoriasis and that it is 
capable of inducing an inflammatory reaction (Groves, et al., 1995). Murine transgenic 
models can provide representative models of the disease, but they can also target or confirm 
if a cytokine such as interleukin 1 or 6 has a role to play in psoriasis. 
Chymotryptic enzyme 
In 2002, Hansson et al., developed a transgenic mouse strain that overexpresses the 
chymotryptic enzyme, which is also overexpressed in the stratum corneum of psoriatic skin. 
This model allows to observe pathological characteristics of psoriasis such as an increase of 
epidermal thickness, hyperkeratosis, severe pruritus and an inflammation of the dermis 
(Hansson et al., 2002).  
 
4.3 Xenotransplantation  
Animal models based on transgenic technology have been used extensively to study the 
pathogenesis of various diseases, including psoriasis (Raychaudhuri et al., 2001). 
Xenotransplantation experiments were performed in which a skin biopsy from a patient or a 
skin equivalent produced in vitro was transplanted on mice from spontaneously mutated or 
genetically modified strains. 
Athymic nude mouse 
Athymic nude mouse have no thymus and therefore no T cells (Raychaudhuri, et al., 2001). 
This model has been used in laboratory to gain insights into the immune system and 
autoimmune diseases. The absence of a functional humoral immune system allows 
transplantation from another species without graft rejection. However, psoriatic skin 
transplanted on athymic mice develops certain histological changes that are not typical of 
psoriasis, such as the absence of parakeratosis and the presence of a granular layer 
(Raychaudhuri, et al., 2001). In past years, athymic nude mice were mainly used to verify if 
there was a difference between involved and uninvolved psoriatic skin (Fraki et al., 1983; 
Krueger et al., 1981). The results showed that involved psoriatic skin maintains its 
psoriasiform histology when transplanted onto nude athymic mice such as epidermal 
thickness and papillomatosis (Fraki, et al., 1983). However, not all the characteristics of the 
pathology were preserved. In fact, psoriatic epidermis did not contain polymorphonuclear 
leucocytes after grafting on athymic nude mice. In this study, uninvolved psoriatic 
epidermis from psoriatic patients seemed to be able to display markers of involved psoriatic 
epidermis independently from the psoriatic host. The authors suggested that the skin itself 
could be the primary cause of psoriasis.  However, some years later, other results obtained 
in a new mouse model, the severe combined immunodeficient mice, suggested that psoriasis 
is a T-cell-mediated disease (Fraki, et al., 1983). 
Severe combined immunodeficient mice (SCID)  
The severe combined immunodeficient mouse model shows a lack of T and B cells, but it 
contains functional neutrophil and mature natural killer (NK) cells with normal cell activity 
(Gudjonsson, et al., 2007). This model has a mutation in the DNA-dependant protein kinase 
gene that is required for successful T-cell and B-cell development (Gudjonsson, et al., 2007). 
It is probably the most widely used relevant model for psoriasis, but the presence of NK 
which are involved in rejection of xenogeneic tissue is a severe inconvenience (Gourlay et 
al., 1998). In fact, single-cell suspensions are rapidly recognized and lysed by mice NK cells 
(Meyerrose et al., 2003). However, in SCID mice, grafts of solid tissues are well tolerated and 
psoriatic characteristics are maintained for several months in the transplantations involving 
psoriatic skin (Raychaudhuri, et al., 2001; Takizawa et al., 1995). Raychaudhuri et al., noticed 
that clinical, histological and immunological features of psoriasis could be maintained for 
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model, some psoriatic characteristics can be observed such as abnormal keratinocyte 
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model, as it is for K14/TGF-α, K5/TGF-β1, K14/KGF models.  
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generate a psoriatic phenotype in transplanted SCID mice, the injection of activated 
lymphocytes and the Stat3 transgenic skin are necessary. These results allow to establish a 
link between keratinocytes and CD4+ T lymphocytes in psoriasis (Danilenko, 2008). 
K14/IL-6 and K14/IL-1α 
A human keratin 14 promoter was used to express IL-6 in the basal cells of epidermal mice 
(Turksen et al., 1992). IL-6 expression did not lead to enhanced epidermal proliferation, but 
it did result in a thicker stratum corneum with an otherwise seemingly normal 
differentiation program. However, IL-6 expression did not lead to leukocytic infiltration 
(Turksen, et al., 1992). In 1995, Groves et al., observed characteristics of psoriasis in a 
transgenic mouse model that expresses high levels of interleukin 1α in basal epidermis. This 
model displayed many characteristics of psoriasis. Uninvolved skin of these animals was 
characterized by hyperkeratosis and dermal mononuclear cell infiltrate of  
macrophage/monocyte lineage (Groves et al., 1995). Inflammatory lesions were marked by 
a mixed cellular infiltrate, acanthosis and parakeratosis in some cases. These results strongly 
indicate that IL-1 is a cytokine which plays an important role in psoriasis and that it is 
capable of inducing an inflammatory reaction (Groves, et al., 1995). Murine transgenic 
models can provide representative models of the disease, but they can also target or confirm 
if a cytokine such as interleukin 1 or 6 has a role to play in psoriasis. 
Chymotryptic enzyme 
In 2002, Hansson et al., developed a transgenic mouse strain that overexpresses the 
chymotryptic enzyme, which is also overexpressed in the stratum corneum of psoriatic skin. 
This model allows to observe pathological characteristics of psoriasis such as an increase of 
epidermal thickness, hyperkeratosis, severe pruritus and an inflammation of the dermis 
(Hansson et al., 2002).  
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there was a difference between involved and uninvolved psoriatic skin (Fraki et al., 1983; 
Krueger et al., 1981). The results showed that involved psoriatic skin maintains its 
psoriasiform histology when transplanted onto nude athymic mice such as epidermal 
thickness and papillomatosis (Fraki, et al., 1983). However, not all the characteristics of the 
pathology were preserved. In fact, psoriatic epidermis did not contain polymorphonuclear 
leucocytes after grafting on athymic nude mice. In this study, uninvolved psoriatic 
epidermis from psoriatic patients seemed to be able to display markers of involved psoriatic 
epidermis independently from the psoriatic host. The authors suggested that the skin itself 
could be the primary cause of psoriasis.  However, some years later, other results obtained 
in a new mouse model, the severe combined immunodeficient mice, suggested that psoriasis 
is a T-cell-mediated disease (Fraki, et al., 1983). 
Severe combined immunodeficient mice (SCID)  
The severe combined immunodeficient mouse model shows a lack of T and B cells, but it 
contains functional neutrophil and mature natural killer (NK) cells with normal cell activity 
(Gudjonsson, et al., 2007). This model has a mutation in the DNA-dependant protein kinase 
gene that is required for successful T-cell and B-cell development (Gudjonsson, et al., 2007). 
It is probably the most widely used relevant model for psoriasis, but the presence of NK 
which are involved in rejection of xenogeneic tissue is a severe inconvenience (Gourlay et 
al., 1998). In fact, single-cell suspensions are rapidly recognized and lysed by mice NK cells 
(Meyerrose et al., 2003). However, in SCID mice, grafts of solid tissues are well tolerated and 
psoriatic characteristics are maintained for several months in the transplantations involving 
psoriatic skin (Raychaudhuri, et al., 2001; Takizawa et al., 1995). Raychaudhuri et al., noticed 
that clinical, histological and immunological features of psoriasis could be maintained for 
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durations of 12-16 weeks, while Sugai et al. conserved the human psoriatic skin transplant 
for up to 22 weeks (Sugai et al., 1998). In this latter study, the psoriatic phenotype was well 
maintained but the histological and immunohistochemical characteristics gradually 
disappeared as lymphocytic infiltration of the psoriatic lesion declined. However, Ghilhar et 
al. showed that injection of T cells from psoriatic plaques in SCID mouse could maintain the 
pathological characteristics longer than in the absence of T cells (Gilhar et al., 1997). These 
results show that the presence of inflammatory cells is necessary to maintain the psoriatic 
phenotype in the SCID model and suggest a role of inflammatory cells in the appearance of 
psoriasis (Gilhar, et al., 1997). 
Spontaneous AGR129 model  
A new model, the AGR129 mice, shows a lack of T and B cells but, contrary to the severe 
combined immunodeficient mice, it has immature NK (Boyman et al., 2004). While the 
natural killer cells are recognized to have a role in transplant rejection (Gourlay, et al., 1998), 
the AGR129 model tolerates xenogenic grafts better than the SCID model. The AGR129 mice 
are deficient in type I(A) and type II(G) IFN receptors in addition to being RAG-2-/-. 
Disruption of both IFN receptors has been previously shown to lead to decreased NK 
cytotoxic activity in vitro and in vivo (Lee et al., 2000). Such deficiencies imply that these 
mice possess immature NK cells which are much less cytotoxic than mature ones (Boyman, 
et al., 2004). Thus, transplant rejection is reduced in this type of mice. Boyman et al. 
demonstrated that human uninvolved psoriatic skin grafted onto AGR129 mice 
spontaneously developed psoriatic plaques without injection of activated immune cells or 
any other exogenous factor. In fact, skin grafts developed a psoriatic phenotype in 28 of 31 
(90 %) grafted mice (Gudjonsson, et al., 2007). Histology of developed plaques was 
comparable to psoriatic lesion biopsies from the same patient. Boyman's team also noticed 
that when they injected an inhibitor of T cells (monoclonal anti-CD3), the psoriatic 
phenotype disappeared. The same phenomenon occurred when they injected an inhibitor of 
TNF-α. Furthermore, in this model, the normal control skin did not develop a psoriasis-like 
phenotype. These observations indicate that activation and proliferation of resident T cells 
are necessary and sufficient to drive psoriasis formation, underlining an essential role for 
immune cells residing within symptomless pre-psoriatic skin (Conrad and Nestle, 2006). 
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Spontaneous mutation      
Homozygous asebia 
+ - + - 
(Brown and 
Hardy, 1988; 
Brown and Hardy, 
1989) 
Flaky skin  + + + - 
(Sundberg, et al., 
1994; Sundberg et 
al., 1997) 
Chronic proliferative dermatitis + + + - (HogenEsch, et al., 1993) 
      
Genetically engineered models      
Targeting the immune system      
HLA-B27/β2 microglobulin rat + + + + 
(Breban, et al., 
1996; Keith, et al., 
2005) 
Hypomorphic CD18 + + + + 
(Bullard, et al., 
1996; Kess, et al., 
2003) 
E (CD103) + + ? + (Schon et al., 2000) 
K14/p40 + ? ? + (Kopp et al., 2001) 
Targeting vascular endothelium      
pTek-tTA/Tie2 + + + + (Voskas, et al., 2005) 
K14/VEGF + + + + (Xia, et al., 2003) 
Targeting epidermal proteins      
K5/Stat3C + + + + (Sano, et al., 2005) 
IKK2 + + ? - (Pasparakis, et al., 2002) 
c-Jun/JunB + + + + (Zenz, et al., 2005) 
K14/KGF + + + - (Guo, et al., 1993) 
K14/TGF- + + ? Some animals (Vassar and Fuchs, 1991) 
K14/IL-20 + + - - (Blumberg, et al., 2001) 
K14/amphiregulin + + + + (Cook et al., 1997) 
K14/IL-1 + + - ? (Groves, et al., 1995) 
K14/IL-6 + - - - (Turksen, et al., 1992) 
K10/BMP-6 + + + + (Blessing et al., 1996) 
Involucrin/integrins + + + + (Carroll et al., 1995) 
Involucrin/MEK1 + + ? + (Hobbs et al., 2004) 
Involucrin/amphiregulin + + + + (Cook et al., 2004) 
Involucrin/IFN- + + + - (Carroll et al., 1997) 
Chymotryptic enzyme + + ? + (Hansson, et al., 2002) 
      
Xenotransplantation      
Athymic nude mouse + + ? - 
(Fraki, et al., 1983; 
Krueger, et al., 
1981) 
SCID 
+ + + + 
(Boehncke et al., 
1994; Gilhar, et al., 
1997; Nickoloff et 
al., 1995; 
Raychaudhuri, et 
al., 2001; Sugai, et 
al., 1998; Takizawa, 
et al., 1995) 
AGR129 + + + + (Boyman, et al., 2004) 
Table 2. In vivo models of psoriasis 
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durations of 12-16 weeks, while Sugai et al. conserved the human psoriatic skin transplant 
for up to 22 weeks (Sugai et al., 1998). In this latter study, the psoriatic phenotype was well 
maintained but the histological and immunohistochemical characteristics gradually 
disappeared as lymphocytic infiltration of the psoriatic lesion declined. However, Ghilhar et 
al. showed that injection of T cells from psoriatic plaques in SCID mouse could maintain the 
pathological characteristics longer than in the absence of T cells (Gilhar et al., 1997). These 
results show that the presence of inflammatory cells is necessary to maintain the psoriatic 
phenotype in the SCID model and suggest a role of inflammatory cells in the appearance of 
psoriasis (Gilhar, et al., 1997). 
Spontaneous AGR129 model  
A new model, the AGR129 mice, shows a lack of T and B cells but, contrary to the severe 
combined immunodeficient mice, it has immature NK (Boyman et al., 2004). While the 
natural killer cells are recognized to have a role in transplant rejection (Gourlay, et al., 1998), 
the AGR129 model tolerates xenogenic grafts better than the SCID model. The AGR129 mice 
are deficient in type I(A) and type II(G) IFN receptors in addition to being RAG-2-/-. 
Disruption of both IFN receptors has been previously shown to lead to decreased NK 
cytotoxic activity in vitro and in vivo (Lee et al., 2000). Such deficiencies imply that these 
mice possess immature NK cells which are much less cytotoxic than mature ones (Boyman, 
et al., 2004). Thus, transplant rejection is reduced in this type of mice. Boyman et al. 
demonstrated that human uninvolved psoriatic skin grafted onto AGR129 mice 
spontaneously developed psoriatic plaques without injection of activated immune cells or 
any other exogenous factor. In fact, skin grafts developed a psoriatic phenotype in 28 of 31 
(90 %) grafted mice (Gudjonsson, et al., 2007). Histology of developed plaques was 
comparable to psoriatic lesion biopsies from the same patient. Boyman's team also noticed 
that when they injected an inhibitor of T cells (monoclonal anti-CD3), the psoriatic 
phenotype disappeared. The same phenomenon occurred when they injected an inhibitor of 
TNF-α. Furthermore, in this model, the normal control skin did not develop a psoriasis-like 
phenotype. These observations indicate that activation and proliferation of resident T cells 
are necessary and sufficient to drive psoriasis formation, underlining an essential role for 
immune cells residing within symptomless pre-psoriatic skin (Conrad and Nestle, 2006). 
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5. In vitro Models 
Contrary to in vivo models, in vitro models are generally characterized by a lack of 
inflammatory cells. Since psoriasis has been described to be an autoimmune disease 
(Bowcock, 2005; Krueger and Bowcock, 2005; Lowes, et al., 2007; Schon and Boehncke, 2005), 
the pertinence of these models has been discussed. It is important to note that (1) 
inflammatory cells can be included in most of the in vitro models, (2) these models allow to 
dissect step by step the mechanisms of psoriasis by isolating or combining the cell types and 
(3) recent studies using animal models, including the IKK2 (Pasparakis, et al., 2002) and 
JunB/c-Jun transgenic mice (Zenz, et al., 2005) are challenging the immunological theory of 
psoriasis. 
 
5.1 Monolayer  
Monolayer models allow, from a small biopsy of pathological skin, the generation of a large 
number of cells sufficient for multiple experiments. In monolayer models, only one cell type 
is considered at a time. Thus, either keratinocytes or fibroblasts will be used to test different 
conditions or observe various characteristics of the disease, such as cell proliferation or 
differentiation. These models allow the isolation of a normal or pathological cell type to 
better understand its specific role. However, they preclude the study of interactions among 
many cellular types (e.g. interactions between the dermis and the epidermis).  
Despite the absence of interaction between the different cell types, monolayer models have 
helped in the discovery of several interesting facts about psoriasis and a better 
understanding of the disease. For example, monolayer cell cultures have helped to realize 
that TGF-α regulates VEGF expression in psoriasis through an autocrine mechanism, 
leading to vascular hyperpermeability and angiogenesis (Detmar et al., 1994). In other 
experiments, van Ruissen et al. found that psoriatic keratinocytes display a lower number of 
cells in S-phase and a shorter duration of G1 compared to normal keratinocytes (van 
Ruissen et al., 1996). Monolayer cultures are widely used and have led to many critical 
observations (Table 3).  
 
5.2 De-epidermized dermis 
Organ culture on de-epidermized dermis 
Mils et al. developed a reconstructed epidermal model with a de-epidermized dermis. A 
psoriatic or normal biopsy was placed dermal side down on the epidermal surface of non 
viable de-epidermized dermis, thus in contact with the remnant basement membrane 
component (Mils et al., 1994). The dead de-epidermized dermis was maintained at the air-
liquid interface on a metallic support. In approximately 15 days, the epidermal layer grew 
out from the punch biopsy to cover the entire de-epidermized dermis. In this model, the 
psoriatic substitutes did not differ significantly from normal substitutes. The only observed 
difference was in LH8 labelling between normal and psoriatic substitutes (Mils, et al., 1994). 
No distinguishing histological or biochemical criteria could be established between normal 
and psoriatic equivalents. 
Keratinocytes on de-epidermized dermis 
Another reconstructed epidermal model was developed with normal adult human 
keratinocytes seeded on de-epidermized dermis (Tjabringa et al., 2008). This model allowed 
controlled induction of psoriasis-associated features and gene expression by the addition of 
relevant pro-inflammatory cytokines (TNF-α, IL-1α, IL-6 and IL-22) and primary 
keratinocytes obtained from donors without history of psoriasis. To produce this model, a 
hollow metal ring was placed on de-epidermized dermis and keratinocytes were seeded 
within the ring (Tjabringa, et al., 2008). Results showed that after the addition of a pro-
inflammatory cytokine mixture, the expression of psoriasis-associated proteins hBD-2 and 
SKALP/elafin for the pro-inflammatory cytokines IL-8 and of TNF-α were increased in the 
skin equivalent, as well as keratinocyte hyperproliferation cells. Tjabringa et al. also showed 
that the addition of all-trans retinoic acid inhibits the expression of psoriasis-associated 
proteins hBD-2 and SKALP/elafin in cytokine-stimulated skin equivalents and reduces 
expression of the normal differentiation marker: keratin 10, as such as acanthosis can be 
observed in psoriatic skin in vivo (Tjabringa, et al., 2008).    
 
5.3 Collagen gels  
Organ culture 
To observe cell proliferation, some studies were done by making a small full-thickness 
punch biopsy into a dermal equivalent, which itself originated from the contraction of a 
collagen gel by dermal fibroblasts (Saiag et al., 1985). The total surface area covered by the 
keratinocytes was used to calculate the cell proliferation percentage. Higher keratinocyte 
proliferation values were obtained in the presence of psoriatic fibroblasts (Saiag, et al., 1985). 
Furthermore, this model led to the conclusion that normal fibroblasts are unable to suppress 
the hyperproliferative growth of psoriatic keratinocytes and that hyperproliferation of 
normal epidermis can be induced both by uninvolved and involved psoriatic fibroblasts 
(Saiag, et al., 1985). 
Models using many cellular types  
Other teams developed skin equivalents composed of two or more cell types to better 
understand cell interactions such as those between keratinocytes and fibroblasts. In general, 
these models imply the isolation of cells from biopsies of normal or affected persons. 
Fibroblasts are extracted from the dermis, expanded and embedded in a collagen gel. 
Keratinocytes are extracted from the epidermis, expanded and plated on top of a collagen 
gel containing fibroblasts. 
Konstantinova et al. have presented a psoriatic collagen gel model which showed a 
psoriasiform phenotype. In fact, in this model, the psoriatic skin equivalent showed a 
thicker epidermis and a loss of filaggrin (Konstantinova et al., 1996). These models enabled 
to examine the effects of normal and psoriatic (involved and uninvolved) fibroblasts on 
epidermal differentiation and cytokine expression. This model led to a number of interesting 
conclusions, such as the confirmation that involved and uninvolved fibroblasts induce 
higher amounts of IL-8 than normal fibroblasts (Konstantinova, et al., 1996). This model 
allowed the observation of interactions between fibroblasts and keratinocytes, but contained 
exogenous material. As previously described, the collagen gel can be very useful for rapid 
production of skin substitutes (Bell et al., 1981a; Bell et al., 1981b; Bell et al., 1979) but, the 
presence of an exogenous scaffold can be disadvantageous for mechanical studies of the 
extracellular matrix and a severe surface reduction of dermal substitutes can be observed 
(Auger et al., 1998; Germain and Auger, 1995). Contraction can be prevented using 
anchorage methods in vitro (Eckes et al., 1995; Germain and Auger, 1995; Grinnell and 
Lamke, 1984; Parenteau et al., 1991; Xu et al., 1996). However, these anchoraged models are 
often fragile and difficult to handle. 
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5. In vitro Models 
Contrary to in vivo models, in vitro models are generally characterized by a lack of 
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(Bowcock, 2005; Krueger and Bowcock, 2005; Lowes, et al., 2007; Schon and Boehncke, 2005), 
the pertinence of these models has been discussed. It is important to note that (1) 
inflammatory cells can be included in most of the in vitro models, (2) these models allow to 
dissect step by step the mechanisms of psoriasis by isolating or combining the cell types and 
(3) recent studies using animal models, including the IKK2 (Pasparakis, et al., 2002) and 
JunB/c-Jun transgenic mice (Zenz, et al., 2005) are challenging the immunological theory of 
psoriasis. 
 
5.1 Monolayer  
Monolayer models allow, from a small biopsy of pathological skin, the generation of a large 
number of cells sufficient for multiple experiments. In monolayer models, only one cell type 
is considered at a time. Thus, either keratinocytes or fibroblasts will be used to test different 
conditions or observe various characteristics of the disease, such as cell proliferation or 
differentiation. These models allow the isolation of a normal or pathological cell type to 
better understand its specific role. However, they preclude the study of interactions among 
many cellular types (e.g. interactions between the dermis and the epidermis).  
Despite the absence of interaction between the different cell types, monolayer models have 
helped in the discovery of several interesting facts about psoriasis and a better 
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5.3 Collagen gels  
Organ culture 
To observe cell proliferation, some studies were done by making a small full-thickness 
punch biopsy into a dermal equivalent, which itself originated from the contraction of a 
collagen gel by dermal fibroblasts (Saiag et al., 1985). The total surface area covered by the 
keratinocytes was used to calculate the cell proliferation percentage. Higher keratinocyte 
proliferation values were obtained in the presence of psoriatic fibroblasts (Saiag, et al., 1985). 
Furthermore, this model led to the conclusion that normal fibroblasts are unable to suppress 
the hyperproliferative growth of psoriatic keratinocytes and that hyperproliferation of 
normal epidermis can be induced both by uninvolved and involved psoriatic fibroblasts 
(Saiag, et al., 1985). 
Models using many cellular types  
Other teams developed skin equivalents composed of two or more cell types to better 
understand cell interactions such as those between keratinocytes and fibroblasts. In general, 
these models imply the isolation of cells from biopsies of normal or affected persons. 
Fibroblasts are extracted from the dermis, expanded and embedded in a collagen gel. 
Keratinocytes are extracted from the epidermis, expanded and plated on top of a collagen 
gel containing fibroblasts. 
Konstantinova et al. have presented a psoriatic collagen gel model which showed a 
psoriasiform phenotype. In fact, in this model, the psoriatic skin equivalent showed a 
thicker epidermis and a loss of filaggrin (Konstantinova et al., 1996). These models enabled 
to examine the effects of normal and psoriatic (involved and uninvolved) fibroblasts on 
epidermal differentiation and cytokine expression. This model led to a number of interesting 
conclusions, such as the confirmation that involved and uninvolved fibroblasts induce 
higher amounts of IL-8 than normal fibroblasts (Konstantinova, et al., 1996). This model 
allowed the observation of interactions between fibroblasts and keratinocytes, but contained 
exogenous material. As previously described, the collagen gel can be very useful for rapid 
production of skin substitutes (Bell et al., 1981a; Bell et al., 1981b; Bell et al., 1979) but, the 
presence of an exogenous scaffold can be disadvantageous for mechanical studies of the 
extracellular matrix and a severe surface reduction of dermal substitutes can be observed 
(Auger et al., 1998; Germain and Auger, 1995). Contraction can be prevented using 
anchorage methods in vitro (Eckes et al., 1995; Germain and Auger, 1995; Grinnell and 
Lamke, 1984; Parenteau et al., 1991; Xu et al., 1996). However, these anchoraged models are 
often fragile and difficult to handle. 
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Other studies have used similar in vitro models. In 2004, Barker et al. developed and 
characterized a new psoriatic skin model in vitro using collagen gels. In this model, psoriatic 
skin substitutes maintained many characteristics of psoriasis such as hyperproliferation, 
overexpression of chemokine receptor CXCR2 and pro-inflammatory genes (TNF-α, INF-γ 
and IL-8) and also increased levels of pro-inflammatory cytokines IL-6 and IL-8 (Barker et 
al., 2004). The substitutes derived from uninvolved psoriatic skin showed the same gene 
expression profile as those derived from involved skin substitutes with an increased 
proliferation rate when compared to normal substitutes. This model suggests that psoriatic 
individuals possess an inherent predisposition to develop the disease phenotype even in the 
absence of T cells (Barker, et al., 2004). As with the model proposed by Konstantinova et al., 
this model contains exogenous material. 
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Monolayer      
IL-15 ? ? ? ? (Krueger and Bowcock, 2005) 
TGF-α regulates VEGF ? ? ? ? (Detmar, et al., 1994) 
S-phase ? ? ? ? (van Ruissen, et al., 1996) 
      
De-epidermized dermis      
Organ culture - - ? - (Mils, et al., 1994) 
Keratinocytes + + ? - (Tjabringa, et al., 2008) 
      
Collagen gel      
Organ culture ? + ? ? (Saiag, et al., 1985) 
Skin substitutes + + ? - (Barker, et al., 2004; Konstantinova, et al., 1996) 
      
Self-assembly      
Skin substitutes + + - - (Bernard, et al., 2007; Jean et al., 2009) 
Table 3. In vitro models of psoriasis 
 
6. A new in vitro psoriatic skin model 
In pharmaceutical sciences, pathological skin substitutes can be very useful for toxicity or 
for cutaneous cellular and molecular biology studies. To be effective, a pathological 
substitute must mimic as closely as possible, morphological and ultrastructural 
characteristics of the pathology. At the present time, although some in vitro and in vivo 
models of psoriasis have been reported to replicate some aspects of the disease, research into 
psoriasis and the subsequent development of therapeutic strategies have been hindered by 
the absence of more relevant models (Jean, et al., 2009).  
As previously shown, a number of teams have carried out in vitro monolayer and stratified 
keratinocyte culture studies to better understand the behaviour of cell types both in an 
individual way, but also to study the interactions between cells with co-culture and 
conditioned media techniques (Mils, et al., 1994; Saiag, et al., 1985; van Ruissen, et al., 1996). 
Some of these studies have shown the importance of the interaction between fibroblasts and 
keratinocytes in psoriatic models. Amongst in vivo models (Gudjonsson et al., 2004), there 
are animal models primarily consisting of grafting a psoriatic skin athymic (Fraki, et al., 
1983) or on severe combined immunodeficient mice (Raychaudhuri, et al., 2001). While the 
clinical and histological characteristics of psoriasis can be maintained for a sufficient period 
of time to test pharmacological drugs, mouse skin is not like human skin. The graft of 
human psoriatic plaques on mice might cause in those animal models an immune response 
that differs from that in humans. Mice used for xenografts are immunocompromised to 
prevent rejection or graft shrinkage; there is no organized lymphatic system to drain the 
grafted skin and a lack of lymphocyte recirculation.  
 
7. Self-assembly method 
7.1 Introduction 
Our team has developed a new psoriatic skin model produced by the self-assembly method. 
This tissue engineered approach is based on the capacity of fibroblasts to create their own 
extracellular matrix in vitro, which makes it possible to obtain cell sheets which are easy to 
handle. A cohesive dermal tissue is obtained by stacking two of these sheets together upon 
which keratinocytes are seeded. This leads to a complete bilayered skin substitute devoid of 
exogenous extracellular matrix proteins and synthetic material. This substitute has many 
histological characteristics close to those of normal human skin (Michel et al., 1999; Pouliot 
et al., 2002). While previous studies using the self-assembly model only used healthy cells, 
the present study creates pathological substitutes with cells isolated from psoriatic biopsies. 
This work strives to develop and characterize a novel in vitro psoriatic skin model produced 
by tissue engineering, which could be used to investigate the mechanisms of abnormal 
keratinocyted growth and to study cell-cell interactions. In this section, previously 
published results will be discussed (Jean, et al., 2009). 
 
7.2 Methods 
The psoriatic substitutes were produced using our modified version of the self-assembly 
method (Fig. 1). The method is, briefly, as follows: human fibroblasts were cultured in the 
presence of ascorbic acid, thus forming manipulatable sheets, which were superimposed 
and incubated for 7 days to form the dermal component. After 7 days of culture, 
keratinocytes were seeded upon this tissue to form the epidermal layer. After another 7 days 
of culture, the substitutes were raised to the air–liquid interface (Michel, et al., 1999; Pouliot, 
et al., 2002). Biopsies were taken after 7, 14 and 21 days of culture at the air–liquid interface 
and analyzed using histological and immunohistochemical techniques. Four different 
combinations of healthy and/or psoriatic cells were used to produce skin substitutes: 
A. Healthy fibroblast/healthy keratinocyte (controls) 
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the present study creates pathological substitutes with cells isolated from psoriatic biopsies. 
This work strives to develop and characterize a novel in vitro psoriatic skin model produced 
by tissue engineering, which could be used to investigate the mechanisms of abnormal 
keratinocyted growth and to study cell-cell interactions. In this section, previously 
published results will be discussed (Jean, et al., 2009). 
 
7.2 Methods 
The psoriatic substitutes were produced using our modified version of the self-assembly 
method (Fig. 1). The method is, briefly, as follows: human fibroblasts were cultured in the 
presence of ascorbic acid, thus forming manipulatable sheets, which were superimposed 
and incubated for 7 days to form the dermal component. After 7 days of culture, 
keratinocytes were seeded upon this tissue to form the epidermal layer. After another 7 days 
of culture, the substitutes were raised to the air–liquid interface (Michel, et al., 1999; Pouliot, 
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and analyzed using histological and immunohistochemical techniques. Four different 
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B.  Psoriatic fibroblast/psoriatic keratinocyte 
C. Psoriatic fibroblast/healthy keratinocyte 
D. Healthy fibroblast/psoriatic keratinocyte 
 
Fig. 1. Self-assembly method 
 
7.3 Results 
In the presence of healthy fibroblasts and healthy keratinocytes (controls), the substitutes 
showed a uniform, smooth and white surface (Fig. 2A). When psoriatic fibroblasts and 
keratinocytes were used to produce the substitutes, the aspect of the substitutes was less 
uniform showing a surface that was thick and whitish in some regions and thinner in others 
(Fig. 2B). The same characteristics were observed with a combination of healthy fibroblasts 
and psoriatic keratinocytes (Fig. 2D). Skin substitutes produced with psoriatic fibroblasts 
and healthy keratinocytes showed the presence of some protuberances (Fig. 2C). 
 
 Fig. 2. Macroscopic analysis of skin substitutes produced with healthy fibroblasts and 
healthy keratinocytes (A), psoriatic fibroblasts and psoriatic keratinocytes (B), psoriatic 
fibroblasts and healthy keratinocytes (C), and healthy fibroblasts and psoriatic keratinocytes 
(D). Pictures were taken after 21 days of culture at the air–liquid interface (scale bar = 2.2 
cm). Reproduced from Jean et al., 2009 © Journal of Dermatological Science. 
Production of 
dermal sheets Air-liquid interface Reconstructed 
dermis 
Suspension of 
keratinocytes
Superposition of 
sheets 
Incubation 
(7 days) 
Masson’s trichrome staining of 5-µm thick biopsies from skin substitutes showed that those 
produced with psoriatic keratinocytes (Fig. 3B and D) had a significantly thicker epidermis 
than the controls (Fig. 3A). The basal layer of the epidermis was less organized in psoriatic 
substitutes (Fig. 3B–D). A compact cornified layer, partly removed during the sectioning 
process of some constructs (ex; Fig. 3D), was observed in combinations containing psoriatic 
keratinocytes. No significant histological difference was noticed between the control and the 
psoriatic fibroblast/healthy keratinocyte combination (Fig. 3A and C), even if the 
macroscopic appearance of this combination showed some protuberances (Fig. 2C), which 
could suggest differences in the thickness of the epidermis. 
 
 Fig. 3. Histological analysis of skin substitutes produced with healthy fibroblasts and 
healthy keratinocytes (A), psoriatic fibroblasts and psoriatic keratinocytes (B), psoriatic 
fibroblasts and healthy keratinocytes (C), and healthy fibroblasts and psoriatic keratinocytes 
(D) (scale bar = 5 µm). Note: the brackets indicate the measured epidermis. Reproduced 
from Jean et al., 2009 © Journal of Dermatological Science. 
 
Epidermal differentiation markers, such as involucrin, appeared in deeper epidermal layers 
of substitutes produced with psoriatic fibroblasts and psoriatic keratinocytes, compared to 
those produced with healthy fibroblasts and healthy keratinocytes (controls) (Fig. 4). An 
overexpression of involucrin, relative to the controls was observed in substitutes produced 
with psoriatic keratinocytes (both combinations). Filaggrin staining showed a diminution or 
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Epidermal differentiation markers, such as involucrin, appeared in deeper epidermal layers 
of substitutes produced with psoriatic fibroblasts and psoriatic keratinocytes, compared to 
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absence of filaggrin expression in substitutes with psoriatic cells compared to those 
produced with healthy fibroblasts and healthy keratinocytes (controls), in which filaggrin 
expression was present from the granular layer (Fig. 4). In the combination of psoriatic 
fibroblasts and healthy keratinocytes, the expression of loricrin was similar to levels seen in 
controls but in the presence of psoriatic keratinocytes (both combinations) its expression 
was partially or completely absent (Fig. 4). In substitutes produced with psoriatic 
keratinocytes, keratin 10 expression was less intense and appeared in the upper layers of the 
epidermis compared to those produced with healthy keratinocytes (both combinations) (Fig. 
4). Some of our immunohistological results, such as loricrin and filaggrin stainings, showed 
the presence of blue nuclei stained with Hoechst in the upper layers of the stratum corneum, 
which is characteristic of parakeratosis. 
 
 Fig. 4. Markers of keratinocyte differentiation in skin substitutes. Samples were prepared 
after 21 days of culture at the air–liquid interface (scale bar = 5 µm). The dotted line 
indicates the dermo-epidermal junction. Reproduced from Jean et al., 2009 © Journal of 
Dermatological Science.  
 
In previous studies, the organization of the stratum corneum lipids was analyzed by 
attenuated total reflectance Fourier transform infrared spectroscopy (ATR-FITR) (Bernard, et 
al., 2007). Results suggested that the stratum corneum of involved psoriatic skin substitutes 
is less organized than that of normal skin substitutes. Bernard et al., also showed that the 
properties of uninvolved psoriatic skin may vary with the severity of the disease. In fact, in 
substitutes made with cells from a patient with 20% of affected body area, the ATR-FITR 
results are similar to controls and uninvolved psoriatic substitutes. However,  in substitutes 
made with cells from a patient with an affected body area 40%, the ATR-FITR results of 
uninvolved psoriatic substitutes are different from those of the control (Bernard, et al., 2007). 
To summarize, this study showed that psoriatic skin substitutes produced by the self-
assembly method have a higher level of lipid disorder and a modification of protein 
conformation in involved psoriatic stratum corneum layer compared to the stratum 
corneum of healthy substitutes (Bernard, et al., 2007). 
 
7.4 Discussion 
The psoriatic substitutes produced by the self-assembly method maintained many psoriasis-
like characteristics such as thicker epidermis, abnormal differentiation, increased 
proliferation and higher levels of lipid disorganization of the stratum corneum. The four 
different keratinocyte/fibroblast combinations show different intensities in the expression of 
the psoriatic phenotype. These combinations allow the observation of interactions between 
healthy/psoriatic cells and fibroblast/keratinocyte cells. This model could become the basis 
of a robust technique to better understand the mechanisms involved in psoriasis and an 
excellent tool for the study of accelerated cellular differentiation of psoriatic keratinocytes. 
In an effort to resolve this complex skin disease, our research first endeavoured to develop a 
psoriatic model devoid of complicating elements such as immunocytes, in order to dissect 
step by step the mechanisms of this pathology. However, this model will be further refined 
to include elements of the immune system which may help establish the roles of different T 
cell subsets and cytokines in psoriasis.  
 
8. Future research 
A large number of psoriatic models have been developed. However, although many 
characteristics of the disease are preserved, no model shows all of them. Experts agreed that 
there was no available model that served all their needs (Zollner, et al., 2004). The choice of 
the most suitable model must always depend on the particular scientific question. The 
ultimate purpose of future research is to find the exact causes of psoriasis in order to find 
specific and effective treatments that will provide a definitive cure for psoriasis with a 
minimum of side effects. In vitro or in vivo pathological models that faithfully mimic this 
disease would be of significant help in the research and development of new treatments. For 
that reason, the development of a more relevant model of psoriasis is a priority for the 
various research efforts that are targeting this disease and would be an important step 
towards its cure. 
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